BTX 1702
Papulopustular Rosacea
Pre-clinical / Early DevelopmentProgram expedited based on mechanistic data
Key Facts
Indication
Papulopustular Rosacea
Phase
Pre-clinical / Early Development
Status
Program expedited based on mechanistic data
Company
About Botanix Pharmaceuticals
Botanix Pharmaceuticals is a global healthcare innovator focused on transforming the treatment landscape for common yet underserved dermatological conditions and infections. The company's key achievement is the FDA approval and US commercial launch of Sofdra™, its first-in-class topical anticholinergic for hyperhidrosis, which is also approved and launched in Japan and South Korea through partners. With a mature pipeline targeting acne, rosacea, atopic dermatitis, and antimicrobial resistance (MRSA), and led by a world-class team with extensive dermatology drug development and commercialization expertise, Botanix is strategically positioned to capture significant market opportunities.
View full company profileTherapeutic Areas
Other Papulopustular Rosacea Drugs
| Drug | Company | Phase |
|---|---|---|
| TP-04 (topical lotilaner) | Tarsus Pharmaceuticals | Phase 2a |
| Epsolay® (benzoyl peroxide) cream | Sol-Gel Technologies | Approved |